Longevity Leader Proposes Combining Senolytic Immunotherapy with Autologous Stem Cells to Restore Consciousness

MIAMI, Oct. 14, 2025 /PRNewswire/ -- Immorta Bio Inc., a scientific longevity company dedicated to Treating Diseases of Aging and Treating Aging as Disease™, today announced publication of its peer-reviewed paper, "Reversing coma by senolytics and stem cells: the future is now," in the Journal of Translational Medicine. Read the full article here

The study, led by Immorta Bio in collaboration with leading U.S. research institutions including the University of California, Loma Linda University, George Washington University, Azimi Cardiovascular Institute, and Ossium Health, presents a new hypothesis for restoring consciousness in coma patients.

The proposed approach combines two of Immorta Bio's complementary technologies — first, using SenoVax™, a senolytic immunotherapy, to eliminate toxic senescent cells to reduce neuroinflammation, which exacerbates brain injury; second, stimulate neural regeneration through the introduction of personalized mesenchymal stem cells (pMSCs) derived from autologous peripheral blood, combined with electrophysiological and pharmacological interventions.

Supported by preclinical data on senescent cell clearance and stem cell–driven neuroregeneration, the paper postulates that this integrated two-step strategy could one day help reverse coma and restore consciousness.

"There have been suggestions of regenerative medicine approaches having some therapeutic effects in coma patients. Our study is the first report, to my knowledge, providing specific sequences of steps for inducing recovery of consciousness in this patient population," Said Thomas Ichim, Ph.D, President and Chief Scientific Officer of Immorta Bio.

"Our senolytic and immortal stem cell technologies open new frontiers — not just for aging, but for conditions once thought irreversible," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio.

‍